Govt. caps trade margins on 137 anti-cancer drugs
The revised prices will become effective from November 9
The National Pharmaceutical Pricing Authority (NPPA) has implemented trade margin rationalisation (TMR) on 137 non-scheduled anti-cancer drugs. This initiative aims to make cancer treatment more affordable and improve access to these essential medicines. The revised prices will be effective from November 9, potentially reducing the maximum retail price (MRP) of these drugs by up to 70%, depending on their existing price structures.
The move builds upon the success of NPPA's 2019 pilot TMR exercise, which capped trade margins for 42 anti-cancer drugs at 30% and led to a reduction in the MRP of 526 brands of non-scheduled anti-cancer medicines by up to 90%. The Expert Committee recommended 137 drugs for inclusion in the TMR list, which will be updated periodically.
Written by urgent.news from The Hindu Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Govt. caps trade margins on 137 anti-cancer drugs thehindu.com
